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www.jacctctabstracts2013.com MONDAY, OCTOBER 28, 2013, 8:00 AM–6:35 PMwall. LV performance was evaluated before (baseline) and immediately after device
implantation by echo.
Results: TCVR was successfully performed in all the animals. Immediately after the
procedure and compared to baseline, LV end-systolic volume was decreased by 54%
(26.98.7 vs. baseline 60.122.2ml, p<0.01) and end-diastolic volume decreased by
34% (54.511.0 vs. baseline 85.620.6ml, p<0.05). Ejection fraction was signiﬁ-
cantly increased by 19.8% (519% vs. baseline 319%, p<0.001) and stroke volume
was preserved (27.56.9 vs. baseline 25.53.8ml, p¼NS).
Conclusions: Minimally invasive thoracoscopically assisted TCVR is feasible and
resulted in signiﬁcant improvement in cardiac volume and ejection fraction in an ovine
infarction model.
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Background: High-risk percutaneous coronary interventions (HRPCI) involving
complex disease and/or depressed cardiac function have become increasingly
common. The potential beneﬁt from short-term mechanical circulatory support is
suggested by observations that intraprocedural hemodynamic compromise may impact
completeness of revascularization and contribute to adverse events. We report
outcomes from a First in Human trial using the HeartMate PHP (Percutaneous Heart
Pump) in patients undergoing HRPCI.PHP is a catheter-based axial ﬂow pump
designed to provide partial left ventricular support of up to 5 lpm and is rapidly
delivered percutaneously via typical femoral insertion. The 12F catheter contains
a distal collapsible covered nitinol cannula with an integrated impeller that expands to
24F when deployed across the aortic valve.
Methods: 10 patients with complex coronary disease and reduced LV function (EF from
26% - 34% prior to PCI) underwent elective HRPCI while on PHP support. Device
success, deﬁned as the deployment, use and removal of PHP without device failure; and
periprocedural measures of hemodynamics and cardiac performance were evaluated.
Major adverse safety and efﬁcacy events were assessed during PHP use and at 30 days.
Results: Among the ﬁrst 3 patients, PHP was successfully deployed in all patients
without complications. There was no periprocedural or follow-up echocardiographic
evidence of aortic regurgitation or valve abnormalities. All patients remained hemo-
dynamically stable while on support and all planned target lesions were revascular-
ized. The PHP was successfully removed in all cases and there were no adverse patient
events while on device support through 30 days. (Outcomes on the full patient series
will be presented when complete.)CARDIAC INDEX MAP PCWP
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Support Baseline
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Support Baseline
On
Support
Pt #1 2.8 3.17 73 65 41 16
Pt #2 2.67 2.45 84 112 11 5
Pt #3 2.3 3.26 97 119 8 9Conclusions: In a First in Human trial involving patients undergoing HRPCI,
hemodynamic support using the HeartMate PHP is feasible and safe.O
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Background: Functional tricuspid regurgitation (TR) is clinically signiﬁcant. TR
predicts mortality independent of LVEF, age or pulmonary artery pressure. PersistentJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstracts/ORAL/25 Years oTR after mitral valve surgery is an independent poor prognostic sign. Tricuspid valve
repair is usually an adjunct to other surgery. We present TRAIPTA, a novel percu-
taneous treatment of functional TR. We demonstrate pre-clinical feasibility in swine.
Methods: Through the femoral vein and under X-ray guidance, the pericardial space
is accessed by puncture through the right atrial appendage (Panel A). A custom
memory-shape delivery device positions a suture circumferentially in the AV groove
(Panel B) and used to deploy a semi-rigid device to apply direct compression to the
tricuspid annulus. The suture is tightened to achieve the desired degree of annulo-
plasty (Panel C), then secured and cut. The atrial appendage access is closed with an
occluder.Results: In naïve swine, trans-auricular pericardial access was easy and safe. The
TRAIPTA device is consistently delivered to the AV groove, tension can be selec-
tively applied to the tricuspid annulus, and RV geometry interactively altered.
Conclusions: Percutaneous treatment of functional TR is feasible in swine using
TRAIPTA.
TCT-128
Transcatheter Implantation of Self-Expandable Vena Cava Valves for Treatment
of Tricuspid Regurgitation: First-Human-Case Description
Hans R. Figulla1, Torsten Doenst2, Marcus Franz2, Ali Hamadanchi3,
Daniel Kretzschmar3, Alexander Lauten2
1Friedrich-Schiller Universitat, Jena, Germany, 2University Hospital Jena, Jena,
Germany, 3Heart Center of the Friedrich-Schiller-University, Jena, Thuringia
Background: Despite the recent advances in interventional treatment of heart valve
disease, no transcatheter approach is established for severe tricuspid regurgitation
(TR). Single valve implantation into the inferior vena cava (IVC) has been suggested,
which however only partially resolves the hemodynamic sequelae of TR. After
extensive preclinical evaluation, we herein report the ﬁrst human case of bi-caval self-
expanding valve implantation (CAVI) in the superior (SVC) and inferior vena cava.
Methods: CAVI was performed in a 83-year-old patient with severe TR, chronic right
heart failure and congestive hepatopathy. Two self-expanding pericardial valves were
custom-made to ﬁt to the anticipated implantation zones in the caval veins of this
patient. Both devices were implanted under ﬂouroscopy using a 27F-catheter and
deployed at the level of the cavo-atrial junction of the SVC and the IVC. To protect
the hepatic veins from backward ﬂow, the inferior valve was aligned just above the
hepatic vein inﬂow and deployed with the valve protruding into the right atrium (RA).
Results: After deployment and during 3-month follow-up excellent valve function
was observed. The procedure resulted in a marked reduction of the pressure in the
SVC and IVC from 27/14mmHg and 28/15mmHg to 21/7mmHg and 13/6mmHg at 3
month, respectively. After implantation symptoms of right heart failure resolved and
did not recurr during follow-up and synthetic liver function recovered. The patients
physical capacity improved with an increase in distance covered in 6-minute-walk-test
from 20m before implantation to 200m at 3 month.
Conclusions: In this ﬁrst-in-man experience, transcatheter CAVI proved feasible and
resulted in persistent hemodynamic and clinical improvement. Further conﬁrmatory
experience with longer follow-up is required to evaluate the clinical beneﬁt of the
procedure.
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Background: Severe tricuspid regurgitation (STR) is a common ﬁnal pathway in
advanced stages of heart failure (HF) and associated with increased morbidity and
mortality. The prevalence of moderate to severe TR is 35% in HF patients occurring in
1.6 Mio patients in the US. In advanced TR stages, the surgical risk is prohibitively
high, alternative approaches are therefore required. Here we describe the feasibility as
well as periprocedural and short-term outcomes of a novel ﬁrst-in-man single caval
and dual caval approach for implantation of the Edwards Sapien XT.
Methods: Vena cava inferior (VCI) single valve approach: to guarantee stable
placement we prepared a landing zone by implanting a self-expanding 30/60-mm
Sinus XL Stent in the IVC segment downstream of the RA. To further downsize thef Interventional Innovation: Novel Therapies and the “Emerging” Device Concepts for 2013 B41
